Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Abstract The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful efficacy in clinical trials. We evaluated the unifying characteristics of anti-amyloid...

Full description

Bibliographic Details
Main Authors: Martin Tolar, Susan Abushakra, John A. Hey, Anton Porsteinsson, Marwan Sabbagh
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Beta amyloid oligomers
Anti-oligomer agents
Anti-amyloid antibodies
APOE4 genotype
Aducanumab
Online Access:http://link.springer.com/article/10.1186/s13195-020-00663-w

Internet

http://link.springer.com/article/10.1186/s13195-020-00663-w

Similar Items